Zinc deficiency is linked to poor prognosis in COVID-19 patients while clinical trials with Zinc demonstrate better clinical outcome. The molecular target and mechanistic details of anti-coronaviral activity of Zinc remain obscure. We show that ionic Zinc not only inhibits SARS-CoV-2 main protease (Mpro) with nanomolar affinity, but also viral replication. We present the first crystal structure of Mpro-Zn 2+ complex at 1.9 Å and provide the structural basis of viral replication inhibition. We show that Zn 2+ coordinates with the catalytic dyad at the enzyme active site along with two previously unknown water molecules in a tetrahedral geometry to form a stable inhibited Mpro-Zn 2+ complex. Further, natural ionophore quercetin increases the anti-viral potency of Zn 2+ . As the catalytic dyad is highly conserved across SARS-CoV, MERS-CoV and all variants of SARS-CoV-2, Zn 2+ mediated inhibition of Mpro may have wider implications.
Human chloride intracellular channel 1 (HsCLIC1) is a dimorphic protein that exists in both soluble enzymatic and membrane-integrated ion channel forms. It is overexpressed in many cancers, yet developing specific inhibitors has been challenging, leaving CLIC proteins largely untargeted. Here, we identified a non-canonical ligand binding site on the soluble enzymatic form of HsCLIC1 and demonstrate that it is druggable with the small molecule inhibitor NSC602247. This cryptic site was discovered using multi-solvent molecular dynamics simulations followed by virtual screening and molecular docking. Using surface plasmon resonance and microscale thermophoresis, we show that NSC602247 binds to HsCLIC1 with micromolar affinity (∼6 μM) and inhibits the proliferation of HT29 colorectal cancer cells. To understand the mechanism of inhibition, we determined the crystal structure of the HsCLIC1-NSC602247 complex. Mechanistically, NSC602247 binding induces oligomerization of soluble HsCLIC1 and reduces its membrane expression, as revealed using flow cytometry. Our data clearly indicate that NSC602247 inhibits HT29 growth by sequestering the protein in a soluble state, thereby blocking its membrane translocation. These findings validate a novel cryptic site on CLIC1 and present a new mechanistic paradigm for inhibiting its pathological function by preventing membrane insertion, offering a promising strategy for targeted therapeutic development.
Hepatitis C virus (HCV) is a major global health burden, associated with chronic liver diseases, including cirrhosis and hepatocellular carcinoma. Viral replication critically depends on conserved cis -acting replication elements (CREs), such as the 5BSL3.2 stem–loop near the 3′ end of the open reading frame. This element forms a long-range kissing-loop interaction with the SL2 domain of the 3′X tail, essential for efficient genome replication. However, the role of host RNA-binding proteins (RBPs) in regulating this RNA–RNA interaction remains poorly understood. To explore this, we investigated whether the host RBP hnRNPA1 modulates HCV replication by targeting the 5BSL3.2 element. Using an integrated approach combining structural biology, biophysics, and biochemical assays, we identify the terminal loop of 5BSL3.2 as a high-affinity binding site for the tandem RNA recognition motifs (RRMs) of hnRNPA1. Our data reveal that adenine-rich residues within the loop are critical for binding specificity. Our results uncover a structural mechanism by which hnRNPA1 binding perturbs the kissing-loop interaction between 5BSL3.2 and the SL2 element of the viral 3′X-tail, which impacts viral replication. This study highlights a previously unrecognized role of hnRNPA1 in modulating viral RNA structure and suggests a novel interface for host-directed antiviral intervention.